Gene therapy injection aims to halt inherited vision loss
NCT ID NCT07241169
Summary
This is a very early-stage study to check the safety of an experimental gene therapy called ZVS106e for people with Stargardt disease, a genetic condition that causes vision loss. Researchers will inject the drug once into the back of one eye in up to 9 participants to see if it is safe and tolerated. They will also look for any early signs that the treatment might help slow or stabilize the disease over one year of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.